Webinar: IMPLEMENTING DRUG DEVELOPMENT STRATEGIES

Maximising the Value of Pharmaceutical Assets

This is the second webinar of a two part series that focuses on improving R&D productivity though adopting an agile approach when choosing an R&D strategy. The literature is replete with examples of drugs failing to deliver value to large and small Biopharmaceutical companies. Some drug failures are unavoidable but other failures can be avoided or some value can be salvaged from the numerous drugs that are "shelved" each year. In the first webinar the presenters described the various strategic options open to drug discoverers and developers to maximize the value of their assets.

In this second webinar we will discuss how to turn the strategic imperatives presented in the first webinar into R&D projects. We will show how the use Thomson Reuters assets with and without company assets, can be used as a starting point to identify repurposing opportunities in order to address such questions as how to identify drug repurposing opportunities, how to gather fact based evidence to chose between those opportunities and finally how to quickly and efficiently evaluate the selected opportunities. Many of these methods apply both to repurposing efforts and to the development of new NME's and drugs for rare and orphan diseases.

Consultants will be joined by Thomson Reuters researchers and influential opinion leaders from the industry to discuss the key challenges of maximizing the value of pharmaceutical assets.

Please join us to participate in one of the hottest topics in R&D today.